Braxia Scientific Corp. (BRAXF)
Braxia Scientific Corp. operates in the Biotechnology industry of the Healthcare sector, headquartered in Mississauga, ON, CA. The stock last traded at $0.00, up 0.00% on the session, giving a market capitalisation of $28,328. On trailing twelve-month figures it carries a trailing P/E of -0.09, a net margin of -697.5%. Its beta of 1.45 implies it has historically moved more than the broad market.
Braxia Scientific Corp. functions as a medical research entity that also runs clinics, offering ketamine therapies to individuals suffering from depression and linked conditions. Beyond its clinical services, the company is actively engaged in discovering and bringing to market novel pharmaceutical compounds and innovative delivery methods. Leveraging its intellectual property development platform, Braxia Scientific innovates by developing derivatives of ketamine and psilocybin, in addition to other psychedelic substances. The organization further owns and operates several multidisciplinary clinics focused on treating a broad spectrum of mental health disorders. Braxia Scientific Corp.'s main office is located in Mississauga, Ontario.
Braxia Scientific Corp. is most often compared with the following Healthcare names: